• slide1
  • slide2
  • slide3
  • slide3
  • slide5
  • slide6
jquery carousel slider by WOWSlider.com v8.1m
Products & Services
Join Our Community


All Products & Services

Research Use Only (RUO)

CE-Marked Assays

View all products

Relevant Publications

Testing for MRD


2015 Product Catalog!

Request our 2015 product catalog


Wall Charts

Request a complimentary copy:

Hematologic Malignancy Testing Algorithm

Clonality Testing Strategy


Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use.

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics


We Are Invivoscribe
See Our Story

LymphoTrack® IGH Somatic Hypermutation Assay for the MiSeq - Now available!

This assay includes a leader sequence primer that targets the entire IGHV gene and allows for the easy determination of SHM in clonal sequences using our LymphoTrack software package. Contact us for more information.

Thanks to everyone who attended Invivoscribe and Genection's workshops at AMP 2014! 

For those unable to attend, look forward to our forthcoming video summaries of both workshops: The MyAML™ Panel: Comprehensive Stratification of AML and Clonality Assessment and Monitoring Using LymphoTrack® Next-Generation Sequencing Assays!



New NGS LymphoTrack® Assays!

The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded to include assays for the detection of IGH Somatic Hypermutation on the Ion PGM™ as well as a suite of assays which allow testing of TRG and IGH simultaneously in a single run on the MiSeq® or the Ion PGM. These assays were all designed for easy integration into a laboratory workflow and include bioinformatics software that allows for easy and streamlined data analysis. Using these assays, both the DNA sequences and frequency distributions of B- and T-cell rearrangements can be obtained. Contact us for more information.


LymphoTrack® Assays for the Ion PGM™ - Now available!

The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded beyond our current MiSeq formatted product line to include assays for TRG and IGH on the Ion PGM™. These assays were designed for easy integration into the laboratory workflow, and include a bioinformatics software that allows for simple and streamlined data analysis providing both DNA sequences and frequency distributions of B- and T-cell rearrangements. Contact us for more information.


View a video of our AMP 2013 Workshop!

We have posted a condensed version of our AMP workshop entitled Clonality Testing by Next-Generation Sequencing: Latest Developments from the New Frontier. This talk was given to a capacity audience in Phoenix, AZ in November 2013, and now you can enjoy highlights at your own convenience. Click here to view.


LymphoTrack® IGH Assay Launched

Invivoscribe has expanded its portfolio of next-generation sequencing (NGS) products with the introduction of the LymphoTrack® IGH Assay (for MiSeq platform). This assay provides unprecedented levels of information in the form of frequency distributions and DNA sequences of rearranged IGH genes. Click here for more information. Contact us to learn more.


In the News

CEOCFO Magazine Interviews Invivoscribe® CEO, Dr. Jeffrey Miller

Invivoscribe® Launches Four CE-Marked NGS-Based LymphoTrack® Dx Assays

For more information, click here.

Genection™ Announces Launch of MyAML™, a Next Generation Sequencing (NGS) Assay for Acute Myeloid Leukemia


We are excited to announce that LabPMM®, our subsidiary reference laboratories in the US and the EU, now offer the only standardized, internationally harmonized and licensed FLT3 Signal Ratio Assay.

Our FLT3 signal ratio (SR) assay tests for both ITD and TKD mutations, providing signal ratios for ITD mutations by comparing the signal intensity of the mutant and wild type amplicon products.


CAP Today

The Feature Story in the May 2013 issue of CAP Today titled: “Molecular clonality testing for lymphoma” highlights the benefits of PCR-based B and T cell clonality assays from Invivoscribe. Click here to view the article.


LabPMM and New York

LabPMM is happy to announce that we have received our New York state clinical lab license. Please contact us with any questions.


Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Menu.

Click here to learn more about Genection. 


January 8, 2014

Invivoscribe embraces the value of constant process improvement


July 16, 2013 Marketwired

Invivoscribe FLT3 Method Patent Claims Upheld 


June 19, 2013 Marketwired
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling


View all News


 h-fb.gif  twitter-new.png  newsvine.png  linkedin.png
Invivoscribe Companies






Meetings and Conferences


AMP Logo

November 4, 2015

Corporate Workshop
AMP 2015 Annual Meeting
Austin, TX, USA


AMP Logo

November 5-7, 2015
AMP 2015 Annual Meeting
Austin, TX, USA 



December 5-8, 2015
2015 ASH Annual Meeting and Exposition
Orlando, FL, USA    


View all Events











web design by specto design